2025
Fertile Ground for Mathematical Modeling: Therapeutic and Diagnostic Nanoparticle Transport in the Glomerulus
Richfield O, Cortez R, Navar L, Pober J, Zheng J, Saltzman W. Fertile Ground for Mathematical Modeling: Therapeutic and Diagnostic Nanoparticle Transport in the Glomerulus. Regenerative Engineering And Translational Medicine 2025, 1-17. DOI: 10.1007/s40883-025-00424-x.Peer-Reviewed Original ResearchChronic kidney diseaseGlomerular diseaseTreat glomerular diseasesKidney diseaseMaintenance of fluid balanceGlomerular filtration barrierTherapeutic optionsGlomerular hemodynamicsGlomerular pathologyFluid balanceGlomerular cellsGlomerular dysfunctionKidney failureRenal glomeruliGlomeruliHuman kidneyGlomerular capillariesNanoparticle transportUrine formationDiseaseFiltration barrierNP transportKidneyNP interactionsPhysiological maintenanceDietary Oxalate Nephropathy Due to Pureed Feeds
Panchal R, Rytting H, Chinnadurai A, Greenbaum L. Dietary Oxalate Nephropathy Due to Pureed Feeds. Kidney Medicine 2025, 101048. DOI: 10.1016/j.xkme.2025.101048.Peer-Reviewed Original ResearchOxalate nephropathyUrinary oxalateHigher intake of foodsSecondary oxalate nephropathyChronic high intakePureed foodsIntake of foodIntake of oxalateCounselling of childrenElevated creatinineKidney biopsyTubular injuryDietary modificationDietary intakeNutritional counselingPrimary hyperoxaluriaKidney functionOxalate intakeGenetic testingKidney failureDietary intake of oxalateKidney stonesKidneyCreatinineNephropathyAutosomal Dominant Polycystic Kidney Disease
Chebib F, Hanna C, Harris P, Torres V, Dahl N. Autosomal Dominant Polycystic Kidney Disease. JAMA 2025, 333: 1708-1719. PMID: 40126492, DOI: 10.1001/jama.2025.0310.Peer-Reviewed Original ResearchMeSH KeywordsAdultAneurysm, RupturedAntidiuretic Hormone Receptor AntagonistsDisease ProgressionGlomerular Filtration RateHumansHypertensionIntracranial AneurysmKidneyPolycystic Kidney, Autosomal DominantRenal Insufficiency, ChronicRenal Replacement TherapySeverity of Illness IndexTolvaptanTreatment OutcomeTRPP Cation ChannelsConceptsAutosomal dominant polycystic kidney diseaseMayo imaging classificationRate of eGFR declineKidney replacement therapyEGFR declineDevelopment of kidney cystsKidney diseaseKidney failureReplacement therapyMm HgVasopressin type 2 receptor antagonist tolvaptanProgression to kidney replacement therapyAnnual rate of eGFR declineAdequate hydrationIntracranial aneurysmsManagement of Autosomal Dominant Polycystic Kidney DiseaseWeight managementProgression to kidney failureDietary sodium restrictionFirst-line treatmentKidney cystsSeverity of kidney diseaseTotal kidney volumeDominant polycystic kidney diseaseDe novo diseaseAutosomal dominant polycystic kidney disease without apparent family history: A single-center experience.
Samuels M, Maarouf O, Zeng W, Hamrahian M, Dahl N, Zhang J. Autosomal dominant polycystic kidney disease without apparent family history: A single-center experience. Clinical Nephrology 2025 PMID: 40329829, DOI: 10.5414/cn111677.Peer-Reviewed Original ResearchAutosomal dominant polycystic kidney diseaseDisease-causing variantsDominant polycystic kidney diseaseFamily historyPolycystic kidney diseaseAutosomal dominant polycystic kidney disease phenotypeKidney diseaseHistory of autosomal dominant polycystic kidney diseaseFamily history of autosomal dominant polycystic kidney diseaseSingle-center experienceApparent family historyThomas Jefferson University HospitalGenetic test resultsADPKD patientsPKD patientsKidney functionGenetic diagnosisGenetic testingUniversity HospitalAccurate diagnosisPatientsKidney failureClinical diagnosisDisease accountPracticing nephrologistsBiomarkers in Autosomal Dominant Tubulointerstitial Kidney Disease
Li M, Jiang L, Liu Z, You R, Li Y, Xiang C, Yang L, Zhang H, Zhou X. Biomarkers in Autosomal Dominant Tubulointerstitial Kidney Disease. Integrative Medicine In Nephrology And Andrology 2025, 12 DOI: 10.1097/imna-d-24-00050.Peer-Reviewed Original ResearchAutosomal dominant tubulointerstitial kidney diseaseChronic kidney diseaseTubulointerstitial kidney diseaseKidney diseaseProgressive chronic kidney diseaseDelay kidney failureVariable clinical featuresUric acid levelsControl blood pressureRenal interstitial fibrosisImprove patient outcomesPotential therapeutic targetClinical featuresClinical manifestationsTreatment optionsInterstitial fibrosisInsidious onsetClinical indicationsDisease progressionTubular proteinuriaEarly diagnosisBlood pressurePathological featuresAdvanced stageKidney failureCharacterization of the Cystic Phenotype Associated with Monoallelic ALG8 and ALG9 Pathogenic Variants
Jawaid T, Elbarougy D, Lavu S, Buia G, Senum S, Olinger E, Yang H, McDonnell S, Bublitz J, Ma J, Audrézet M, Madsen C, Schauer R, Baker T, Gregory A, Orr S, Barroso-Gil M, Neatu R, Joli G, Dahl N, Kline T, Gillion V, Dahan K, Jouret F, Perrone R, Steinman T, Peters D, Gitomer B, Watnick T, Coto E, Chebib F, Hogan M, Olson J, Larson N, Ars E, Halbritter J, Demoulin N, Torres V, Sayer J, Gall E, Harris P. Characterization of the Cystic Phenotype Associated with Monoallelic ALG8 and ALG9 Pathogenic Variants. Journal Of The American Society Of Nephrology 2025, 36: 1056-1071. PMID: 39899384, PMCID: PMC12147961, DOI: 10.1681/asn.0000000613.Peer-Reviewed Original ResearchPathogenic variantsAutosomal dominant polycystic kidney diseaseAutosomal dominant polycystic kidney disease geneCystic kidneysKidney cystsPKD phenotypeSequence dataAutosomal dominant polycystic liver diseaseALG8ALG9Kidney phenotypeGenesDominant polycystic kidney diseaseInherited nephropathyAnalysis of individualsPathogenic changesPolycystic kidney diseasePKD1PhenotypeKidney diseaseMcbBMutationsVariantsLiver diseaseKidney failureChronic kidney disease
Romagnani P, Agarwal R, Chan J, Levin A, Kalyesubula R, Karam S, Nangaku M, Rodríguez-Iturbe B, Anders H. Chronic kidney disease. Nature Reviews Disease Primers 2025, 11: 8. PMID: 39885176, DOI: 10.1038/s41572-024-00589-9.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseKidney functionPresence of concomitant risk factorsRisk factorsSodium-glucose transporter 2Abnormalities of kidney functionConcomitant risk factorsManagement of patientsExcretory kidney functionKidney replacement therapyRenin-angiotensin systemModifiable risk factorsAssociated with accelerated cardiovascular diseaseSecondary hyperparathyroidismSequential injuryPersistent abnormalitiesReplacement therapySodium-glucoseCardiovascular morbidityMetabolic acidosisSevere infectionsCKD progressionKidney diseaseKidney failureTransporter 2
2024
Novel PIBF1 Pathogenic Variant in Three Siblings with Joubert Syndrome Type 33
Aynekin B, Samur B, Gumus U, Bilguvar K, Gulec A, Efthymiou S, Gumus H, Caglayan A, Per H. Novel PIBF1 Pathogenic Variant in Three Siblings with Joubert Syndrome Type 33. Molecular Syndromology 2024, 1-10. DOI: 10.1159/000543107.Peer-Reviewed Original ResearchMolar tooth signRare autosomal recessive disorderOptic nerve atrophySevere renal diseaseAutosomal recessive disorderHomozygous nonsense mutationWhole-exome sequencingNerve atrophyRenal atrophyDisease-causing genesClinical spectrumClinical featuresDysmorphic featuresClinical manifestationsPhenotypic expansionDiagnostic awarenessHomozygous mutationJoubert syndromePathogenic variantsPatient's seizuresRecessive disorderRenal diseaseNonsense mutationDevelopmental delayKidney failureTreatment Effect Heterogeneity in Acute Kidney Injury Incidence Following Intravenous Antihypertensive Administration for Severe Blood Pressure Elevation During Hospitalization
Ghazi L, Chen X, Harhay M, Hu L, Biswas A, Peixoto A, Li F, Wilson F. Treatment Effect Heterogeneity in Acute Kidney Injury Incidence Following Intravenous Antihypertensive Administration for Severe Blood Pressure Elevation During Hospitalization. American Journal Of Kidney Diseases 2024, 85: 442-453. PMID: 39580068, DOI: 10.1053/j.ajkd.2024.09.011.Peer-Reviewed Original ResearchAcute kidney injuryAcute kidney injury incidenceSevere hypertensionIV antihypertensivesAntihypertensive treatmentBlood pressureRisk of acute kidney injuryAbstractText Label="SETTINGS &Blood pressure elevationSevere blood pressure elevationSystolic blood pressureIdentifying treatment optionsAntihypertensive administrationKidney injuryAbstractText Label="RATIONALETreatment optionsAntihypertensive effectBP elevationPressure elevationPatient characteristicsDiastolic BPPatientsKidney failureAntihypertensivesHospital admissionLong-term outcomes of IgA nephropathy in China
Shen X, Chen P, Liu M, Liu L, Shi S, Zhou X, Lv J, Zhang H. Long-term outcomes of IgA nephropathy in China. Nephrology Dialysis Transplantation 2024, 40: 1137-1146. PMID: 39557651, DOI: 10.1093/ndt/gfae252.Peer-Reviewed Original ResearchConceptsEnd-stage kidney diseaseLong-term outcomesTime-averaged proteinuriaKidney outcomesPrognosis of immunoglobulin A nephropathyFollow-upMonths of follow-upKidney failureOutcome of IgA nephropathyAssociated with kidney failureKidney survival ratesPeking University First HospitalRestricted cubic spline analysisRisk of end-stage kidney diseaseLong-term kidney survivalBiopsy-proven IgANOutcome of IgANKaplan-Meier analysisAnnual event rateLong-term prognosisCurrent treatment strategiesImmunoglobulin A nephropathyRisk of kidney failureCubic spline analysisProteinuria remissionDevelopment of a Novel Intraperitoneal Icodextrin/Dextrose Solution for Enhanced Sodium Removal
Asher J, Ivey-Miranda J, Maulion C, Cox Z, Borges-Vela J, Mendoza-Zavala G, Cigarroa-Lopez J, Silva-Rueda R, Revilla-Monsalve C, Moreno-Villagomez J, Ramos-Mastache D, Goedje O, Crosbie I, McIntyre C, Finkelstein F, Turner J, Testani J, Rao V. Development of a Novel Intraperitoneal Icodextrin/Dextrose Solution for Enhanced Sodium Removal. Kidney Medicine 2024, 7: 100938. PMID: 39790231, PMCID: PMC11714391, DOI: 10.1016/j.xkme.2024.100938.Peer-Reviewed Original ResearchPD solutionsPeritoneal dialysisSodium removalIcodextrin PD solutionExposure of miceLong-term safetyClearance of uremic toxinsChronic therapyEdematous disordersStructural tissue changesAdverse eventsRemoval therapyEfficacy resultsHeart failureEvaluate safetyNet ultrafiltrationUremic toxin clearanceAnimal modelsIcodextrinKidney failureUremic toxinsTissue changesAscending concentrationsEfficient ultrafiltrationEfficacyTolvaptan and Autosomal Dominant Polycystic Kidney Disease Progression in Individuals Aged 18-35 Years: A Pooled Database Analysis
Chebib F, Dahl N, Zhou X, Garbinsky D, Wang J, Nunna S, Oberdhan D, Fernandes A. Tolvaptan and Autosomal Dominant Polycystic Kidney Disease Progression in Individuals Aged 18-35 Years: A Pooled Database Analysis. Kidney Medicine 2024, 7: 100935. PMID: 39810815, PMCID: PMC11731472, DOI: 10.1016/j.xkme.2024.100935.Peer-Reviewed Original ResearchAutosomal dominant polycystic kidney diseaseMedian Follow-UpEGFR decline rateFollow-upEGFR declineIncreased risk of rapid progressionAutosomal dominant polycystic kidney disease patientsKidney failureRisk of rapid progressionStandard of care treatmentBenefits of tolvaptanTolvaptan-treated patientsChronic kidney disease stageEfficacy of tolvaptanPolycystic kidney disease progressionEffect of tolvaptanAutosomal dominant polycystic kidney disease progressionKidney disease stageDominant polycystic kidney diseaseLong-term efficacyFollow-up periodKidney disease progressionMayo imaging classificationPolycystic kidney diseaseMixed-effects modelsAssociation of chronic kidney disease and kidney failure with replacement therapy with procedural and long-term outcomes after first-generation Watchman device: Insights from the NCDR LAAO Registry
Munir M, Tan Z, Pun P, Wang Y, Tandar A, Darden D, Hsu J, Friedman D, Curtis J, Freeman J. Association of chronic kidney disease and kidney failure with replacement therapy with procedural and long-term outcomes after first-generation Watchman device: Insights from the NCDR LAAO Registry. Heart Rhythm 2024, 22: 1443-1451. PMID: 39515495, DOI: 10.1016/j.hrthm.2024.10.071.Peer-Reviewed Original ResearchChronic kidney diseaseLong-term outcomesLeft atrial appendage occlusionAssociation of chronic kidney diseaseNational Cardiovascular Data Registry LAAO RegistryReplacement therapyAdverse eventsAtrial fibrillationKidney diseaseKidney failureAssociated with higher ratesIn-Hospital DeathRisk of strokeRate of strokeBilling claimsAF patientsProcedural complicationsAppendage occlusionWatchman deviceMultivariate analysisKFRTHigh riskPatientsRegistryComplicationsAutosomal Dominant Polycystic Kidney Disease
Suarez M, Titan S, Dahl N. Autosomal Dominant Polycystic Kidney Disease. Advances In Kidney Disease And Health 2024, 31: 496-503. PMID: 39577883, DOI: 10.1053/j.akdh.2024.07.003.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseaseDelivery of personalized treatmentKidney diseaseKidney failureMinority of patientsDominant polycystic kidney diseaseEnd-stage kidney diseaseRisk of kidney failureCause of end-stage kidney diseasePolycystic kidney diseaseBlood pressure managementMassive hepatomegalySevere complicationsPolycystic liverIntracranial aneurysmsPersonalized treatmentNatural historyOrgan systemsDiseaseTreatmentKidneyPressure managementLiverSystem conditionsPreimplantationThe pathogenesis of IgA nephropathy and implications for treatment
Cheung C, Alexander S, Reich H, Selvaskandan H, Zhang H, Barratt J. The pathogenesis of IgA nephropathy and implications for treatment. Nature Reviews Nephrology 2024, 21: 9-23. PMID: 39232245, PMCID: PMC7616674, DOI: 10.1038/s41581-024-00885-3.Peer-Reviewed Original ResearchIgA nephropathyComplement activationDisease pathogenesisB cell primingMucosal immune systemPathogenesis of IgA nephropathyChronic kidney diseaseTargeting different pathwaysPlasma cellsPrimary glomerulonephritisTreatment optionsIgA antibodiesKidney diseaseImmune complexesTriggering inflammationKidney damageGut mucosaObservational studyKidney failureImmune systemLong-term outlookPathway activationPathogenesisIgANNephropathyOpportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory
Cellini B, Baum M, Frishberg Y, Groothoff J, Harris P, Hulton S, Knauf F, Knight J, Lieske J, Lowther W, Moochhala S, Nazzal L, Tasian G, Whittamore J, Sas D. Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory. Kidney International Reports 2024, 9: 3083-3096. PMID: 39534212, PMCID: PMC11551133, DOI: 10.1016/j.ekir.2024.08.031.Peer-Reviewed Original ResearchPlasma proteomics of acute tubular injury
Schmidt I, Surapaneni A, Zhao R, Upadhyay D, Yeo W, Schlosser P, Huynh C, Srivastava A, Palsson R, Kim T, Stillman I, Barwinska D, Barasch J, Eadon M, El-Achkar T, Henderson J, Moledina D, Rosas S, Claudel S, Verma A, Wen Y, Lindenmayer M, Huber T, Parikh S, Shapiro J, Rovin B, Stanaway I, Sathe N, Bhatraju P, Coresh J, Rhee E, Grams M, Waikar S. Plasma proteomics of acute tubular injury. Nature Communications 2024, 15: 7368. PMID: 39191768, PMCID: PMC11349760, DOI: 10.1038/s41467-024-51304-x.Peer-Reviewed Original ResearchConceptsAcute tubular injuryAcute kidney injuryPathway analysisOrganelle stress responsesSingle-cell RNA sequencingKidney Precision Medicine ProjectKidney diseaseSOMAscan proteomics platformProgression to kidney failureRNA sequencingBiological pathwaysGene expressionStress responseNon-invasive biomarkersProteomics platformMannose receptor 1Kidney injuryTubular injuryImmune regulationReceptor 1Macrophage mannose receptor 1Host responseBiomarker proteinsPrecision Medicine ProjectKidney failureA plain language summary of the NefIgArd trial: Nefecon for the treatment of patients with immunoglobulin A nephropathy
Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich H, Rovin B, Barratt J. A plain language summary of the NefIgArd trial: Nefecon for the treatment of patients with immunoglobulin A nephropathy. Future Rare Diseases 2024, 4: 2380247. DOI: 10.1080/23995270.2024.2380247.Peer-Reviewed Original ResearchInterleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor
Brösecke F, Pfau A, Ermer T, Dein Terra Mota Ribeiro A, Rubenbauer L, Rao V, Burlein S, Genser B, Reichel M, Aronson P, Coca S, Knauf F. Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor. Scientific Reports 2024, 14: 11323. PMID: 38760468, PMCID: PMC11101424, DOI: 10.1038/s41598-024-61808-7.Peer-Reviewed Original ResearchConceptsIL-16 levelsIL-16Dialysis patientsCardiovascular eventsConcentrations of IL-16Kidney failureUremic toxinsCardiovascular diseaseCompared to healthy individualsPlasma oxalate concentrationActivated immune cellsAssociated with cardiovascular diseaseIL-16 concentrationCytokine IL-16Cardiovascular risk factorsNo significant associationPlasma oxalateInflammatory markersImmune cellsCytokine concentrationsInterleukin-16US patientsCohort 1Cardiovascular outcomesHealthy individualsCapacity for the management of kidney failure in the International Society of Nephrology Middle East region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA)
Karam S, Amouzegar A, Alshamsi I, Al Ghamdi S, Anwar S, Ghnaimat M, Saeed B, Arruebo S, Bello A, Caskey F, Damster S, Donner J, Jha V, Johnson D, Levin A, Malik C, Nangaku M, Okpechi I, Tonelli M, Ye F, Abu-Alfa A, Savaj S, Authors R, Abou-Jaoudeh P, Al Hussain T, Al Salmi I, Alrukhaimi M, Alyousef A, Bahous S, Cai G, Hassan H, Cho Y, Davids M, Davison S, Diongole H, Divyaveer S, Ekrikpo U, Ethier I, Fung W, Ghimire A, Hooman N, Houston G, Htay H, Ibrahim K, Irish G, Jindal K, Kelly D, Lalji R, Mitwali A, Mortazavi M, Nalado A, Neuen B, Olanrewaju T, Osman M, Ossareh S, Petrova A, Riaz P, Saad S, Sakajiki A, See E, Sozio S, Tiv S, Tungsanga S, Viecelli A, Wainstein M, Wannous H, Yeung E, Zaidi D. Capacity for the management of kidney failure in the International Society of Nephrology Middle East region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA). Kidney International Supplements 2024, 13: 57-70. PMID: 38618498, PMCID: PMC11010631, DOI: 10.1016/j.kisu.2024.01.009.Peer-Reviewed Original ResearchChronic kidney disease registryImprovement of early detectionHealth-related quality-of-life scoresLower health-related quality-of-life scoresGlobal Kidney Health AtlasChronic kidney diseaseHealth information systemsConservative kidney managementLevels of careBurden of kidney diseaseQuality-of-life scoresPrevalence of chronic kidney diseaseManagement of kidney failureIncidence of kidney transplantationKidney failure treated with dialysisSymptom burdenKidney diseaseKidney managementPeritoneal dialysisTailored guidelinesKidney transplantationKidney failureMiddle East regionEast regionRegistry
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply